Receptor News and Research

RSS

Testosterone may lead to greater heart attack risk in men than women

Testosterone might be involved in explaining why men have a greater risk of heart attacks than women of similar age, according to a study funded by the British Heart Foundation and the Biotechnology and Biological Sciences Research Council. The findings, published in the journal Scientific Reports, could lead to new therapies to help reduce heart attack risk.

21 Apr 2016

Small piece of detoxified E. coli wall makes mice lose natural sweet tooth, study finds

Putting just a tiny piece of the wall of detoxified E. coli into their gut make mice lose their natural sweet tooth, researchers report.

20 Apr 2016

New drug combination before surgery may improve outcomes in breast cancer patients

Results from the I-SPY 2 trial show that giving patients with HER2-positive invasive breast cancer a combination of the drugs trastuzumab emtansine (T-DM1) and pertuzumab before surgery was more beneficial than the combination of paclitaxel plus trastuzumab.

19 Apr 2016

Researchers find mechanism behind pancreatic cancer cells' resistance to certain drugs

Pancreatic cancer is on track to become the second leading cause of cancer-related deaths by 2020. These statistics are due, in part, to pancreatic cancer's resistance to most targeted cancer therapies. Working with pancreatic cancer cells, researchers have now found a mechanism that could be responsible for the cancer's resistance to at least one targeted approach.

19 Apr 2016

Penn researchers report results of CAR therapy trial in brain cancer patients

Immune cells engineered to seek out and attack a type of deadly brain cancer known as glioblastoma (GBM) were found to have an acceptable safety profile and successfully migrate to and infiltrate tumors, researchers from Penn Medicine and Harvard University reported at the AACR Annual Meeting 2016.

19 Apr 2016

Inhibiting adrenaline receptors reduces breast cancer brain metastases

While we look to invent new medicines to treat cancer, a parallel approach to repurpose existing medicines may be highly effective. Stress, mediated by adrenaline, has been suspected to promote cancer growth and this research study shows that by blocking adrenaline receptors in breast cancers, they are less successful in spreading to and growing in the brain.

19 Apr 2016

Researchers use BMG LABTECH's microplate readers to measure binding events in kinetic over minutes

Single reading events of a signaling molecule at a given time should no longer be considered as the only insightful indicator to predict the usefulness of a new drug candidate.

From BMG LABTECH GmbH 19 Apr 2016

Studies confirm benefit of plasma genotyping to predict treatment outcomes for NSCLC patients

The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland. Researchers however warned that plasma tests are unlikely to fully replace tissue biopsies.

18 Apr 2016

LOXO-101 drug shows efficacy with tumor regression in varied types of genetically defined cancer

A phase I study of the drug LOXO-101 appears to significantly reduce tumors in patients with varied types of genetically defined cancer, according to a study led by The University of Texas MD Anderson Cancer Center.

18 Apr 2016

Palovarotene drug may prevent multiple musculoskeletal problems linked with FOP

New research in laboratory animals suggests that the drug palovarotene may prevent multiple skeletal problems caused by a rare but extremely disabling genetic bone disease, and may even be a candidate for use in newborn babies with the condition.

15 Apr 2016

Improving body clock could protect against metabolic syndrome

Essential biological processes are managed by an internal timer or body clock. When the body clock gets out of whack, conditions such as metabolic syndrome can occur.

15 Apr 2016

M10 peptide could help protect systemic sclerosis patients against fibrotic damage

The results of preclinical studies by investigators at the Medical University of South Carolina (MUSC) reported in the April 2016 issue of Translational Research suggest that the M10 peptide could help protect against fibrotic damage in patients with systemic sclerosis, particularly in those who develop interstitial lung diseases (ILD), its deadliest complication.

15 Apr 2016

AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

AstraZeneca today reported new Phase I extended follow-up data on osimertinib in both first- and second-line treatment of patients with non-small cell lung cancer (NSCLC), at the European Lung Cancer Conference (ELCC) 2016. Late-breaker presentations reinforced the efficacy and safety profile for osimertinib previously seen in the AURA clinical trials programme.

15 Apr 2016

HLA-C/KIR genotype linked to HBeAg-positive HBV interferon response

The human leucocyte antigen-C and killer immunoglobin-like receptor genotypes are associated with response to interferon-based therapy in patients with chronic hepatitis B virus infection positive for hepatitis B e antigen, say researchers.

13 Apr 2016

Scientists reveal mechanism involved in regulation of lymphangiogenesis

After an injury to tissues, such as in organ transplantation, the body grows new lymphatic vessels in a process known as lymphangiogenesis. A new study in Nature Communications reveals a mechanism involved in the regulation of this process, specifically in corneal transplants and infectious eye disease.

13 Apr 2016

Study reveals TRPV2 protein as new target for chronic pain, cancer treatments

In a recent paper published in Nature Communications, a group of Case Western University School of Medicine researchers presented their discovery of the full-length structure of a protein named Transient Receptor Potential Vanilloid subtype 2 (TRPV2).

13 Apr 2016

Study reveals low rates of targeted drug use among older black women with early-stage breast cancer

The advent of targeted drugs for a specific type of breast cancer - HER2 positive - has dramatically improved survival rates for women with the disease. But a study led by researchers at the University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center reveals low rates of use of a targeted drug among older women with early-stage breast cancer of this type, and even lower rates for older black women.

13 Apr 2016

RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

RedHill Biopharma Ltd. (NASDAQ; RDHL) (TASE: RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it has initiated a randomized, double-blind, 2-arm parallel group Phase II clinical study in the U.S. evaluating the safety and efficacy of BEKINDA™ 12 mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

13 Apr 2016

Manipulation of signals in nervous system can enhance recovery after traumatic injury

Neurobiologists at UC San Diego have discovered how signals that orchestrate the construction of the nervous system also influence recovery after traumatic injury. They also found that manipulating these signals can enhance the return of function.

12 Apr 2016

Newly developed light-activated tool could pave way for new generation of anti-diabetic drugs

Researchers have developed a light-activated tool to show how drugs need to be adapted to combat type 2 diabetes.

12 Apr 2016

Receptor News and Research

Testosterone may lead to greater heart attack risk in men than women

Small piece of detoxified E. coli wall makes mice lose natural sweet tooth, study finds

New drug combination before surgery may improve outcomes in breast cancer patients

Researchers find mechanism behind pancreatic cancer cells' resistance to certain drugs

Penn researchers report results of CAR therapy trial in brain cancer patients

Inhibiting adrenaline receptors reduces breast cancer brain metastases

Researchers use BMG LABTECH's microplate readers to measure binding events in kinetic over minutes

Studies confirm benefit of plasma genotyping to predict treatment outcomes for NSCLC patients

LOXO-101 drug shows efficacy with tumor regression in varied types of genetically defined cancer

Palovarotene drug may prevent multiple musculoskeletal problems linked with FOP

Improving body clock could protect against metabolic syndrome

M10 peptide could help protect systemic sclerosis patients against fibrotic damage

AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

HLA-C/KIR genotype linked to HBeAg-positive HBV interferon response

Scientists reveal mechanism involved in regulation of lymphangiogenesis

Study reveals TRPV2 protein as new target for chronic pain, cancer treatments

Study reveals low rates of targeted drug use among older black women with early-stage breast cancer

RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

Manipulation of signals in nervous system can enhance recovery after traumatic injury

Newly developed light-activated tool could pave way for new generation of anti-diabetic drugs

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News